Form 4: Sangamo Therapeutics Executive Reports Stock Transactions

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, reports acquisition and disposal of common stock and stock options related to vesting of restricted stock units and tax withholding.

Summary

• Nathalie Dubois-Stringfellow, SVP-Chief Development Officer of Sangamo Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The report includes transactions from February 24, 2025, and February 25, 2025.
• These transactions involve the acquisition and disposal of common stock due to the vesting of restricted stock units (RSUs) and the subsequent surrender of shares for tax withholding.
• Dubois-Stringfellow also acquired 560,000 stock options on February 25, 2025, exercisable from February 24, 2035.
• Following the reported transactions, Dubois-Stringfellow beneficially owns 833,405 shares of common stock and 560,000 stock options.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. While the acquisition of shares and options is generally positive, the disposal of shares for tax withholding is neutral. Overall, the sentiment is moderately positive.

Positives

• The acquisition of 120,000 shares through an RSU grant indicates continued investment in the company by the executive.
• The grant of 560,000 stock options incentivizes the executive to contribute to the company's long-term success.

Future Outlook

The document details the vesting schedule of existing RSU grants through February 24, 2026, and January 22, 2026, and the vesting of new RSU grants and stock options.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Comparison to Industry Standards

• Executive compensation packages often include a mix of salary, stock options, and restricted stock units (RSUs).
• The vesting schedules described in the document (quarterly or monthly installments after a one-year cliff) are typical for RSU and stock option grants.
• Tax withholding practices related to RSU vesting are standard procedure across publicly traded companies.
• Comparable companies in the biotechnology sector, such as CRISPR Therapeutics and Editas Medicine, also utilize similar equity compensation structures for their executives.

Stakeholder Impact

• The transactions have a minor impact on shareholders, as they reflect routine compensation-related activities.
• Employees may be affected by the vesting of their own stock options and RSUs.

Key Dates